MIGS surgery for the Treatment of Glaucoma at the Time of Cataract Surgery
If you have glaucoma and also need cataract surgery, it can feel overwhelming and leave you with lots of questions; namely, which should you address first?
Eye Medical Clinic, a leader in ophthalmic treatments and technologies, has great news for you. We offer several choices in the treatment of your glaucoma that can be performed at the time of cataract surgery, saving you time and money. With these options, a large majority of patients achieve independence from glasses as well as from glaucoma medications after surgery.
iStent has been called a game changer in glaucoma treatment. It can be implanted at the time of cataract surgery at Eye Medical Clinic by one of our expertly trained surgeons.
The tiny iStent is placed in the eye during cataract surgery, saving you time and money; and most importantly, your sight. The device is so small that you won’t feel it or even know it is there after surgery. iStent can effectively lower eye pressure by improving the outflow of fluid from the eyes.
Dr. Bagga was the very first ophthalmologist to utilize iStents in the state of Arizona, and has been at the forefront of this procedure since its inception.
iStent creates a permanent opening through the blockage to improve the eye’s natural fluid outflow. iStent facilitates the outflow of fluid to the meshwork of the eye to help lower intraocular pressure.
Several clinical trials have shown that the implantation of iStent in conjunction with cataract surgery can result in an even greater reduction of IOP and decrease a patient’s need for medications.*
Call Eye Medical Clinic today to talk to an experienced glaucoma specialist and to discover which glaucoma treatment is best for you.
*Samuelson TW, Katz LJ, Wells JM, et al; US iStent Study Group. Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract. Ophthalmology. 2011;118:459-467.
The CyPass Micro-Stent is an amazing advancement in the care of individuals with mild to moderate primary open-angle glaucoma. CyPass helps reduce or even eliminate your need for prescription eye drops to control your intraocular pressure (IOP).
CyPass works in harmony with your eye’s anatomy. In a minimally-invasive procedure, it is placed in the supraciliary space and assists with fluid outflow via the uveoscleral pathway. This is a little different than iStent, which is placed in the trabecular meshworks and helps with outflow through a different avenue. The CyPass device is tiny (approximately 6mm x 0.5mm)!
The great news? Approximately 70% of CyPass patients are able to reduce or eliminate their glaucoma drops and still achieve their target IOP.
Trabectome is a minimally-invasive glaucoma procedure that increases flow into the natural drainage system of your eye by removing part of the clogged drainage system (trabecular meshwork). It can be performed as a single surgery to address glaucoma or combined with cataract surgery.
According to the Glaucoma Research Foundation, Trabectome usually lowers the eye pressure by about 30%, while also decreasing the number of glaucoma eye drops that need to be taken.
Ab-interno canaloplasty is a very safe and effective procedure that provides significant and sustained reduction of IOP and medication use. A microcatheter is used to “unclog” the drainage system of the eye resulting in restoration of normal drainage and reduction in the IOP.
It can either be used as a first line option for patients with mild-to-moderate glaucoma whose IOP is uncontrolled with eye drops/laser or it can be combined with cataract surgery in patients with mild-to-moderate glaucoma to help eliminate or reduce the dependence on eye drops for glaucoma.
XEN Gel Stent is a tiny gelatin implant that helps bypass the blocked drainage system by creating a small channel in the eye to drain fluid and help reduce the IOP. It is about the size of an eyelash and is placed underneath the transparent tissue that covers the white of the eye. It is indicated for glaucoma patients with failed previous surgical treatment or those who are uncontrolled with maximal medical therapy.
Studies have shown a 40% reduction in IOP at 36 months and a 74% reduction in glaucoma medications.*
*Reitsamer H. A., Lenzhofer M., Hohensinn M. H. Ab interno approach to subconjunctival space: first 567 eyes treated with new minimally invasive gel stent for treating glaucoma. Paper presented at: ASCRS. ASCRS/ASOA Annual Symposium and Congress; 2015 Apr 17–21; San Diego, CA. 2015.
At Eye Medical Clinic, Dr. Mona Bagga is an expert on all the traditional and MIGS glaucoma surgeries. After careful evaluation of the type and severity of your glaucoma, age, lifestyle and a host of others factors, she will recommend a personalized treatment plan that is customized for your individual needs.